Generic placeholder image

Current Topics in Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 1568-0266
ISSN (Online): 1873-4294

Caspase Inhibitors: A Pharmaceutical Industry Perspective

Author(s): Steven D. Linton

Volume 5, Issue 16, 2005

Page: [1697 - 1717] Pages: 21

DOI: 10.2174/156802605775009720

Price: $65

Abstract

Caspase inhibition has been demonstrated to be therapeutically effective in moderating excessive programmed cell death, or apoptosis. Publications detailing programs in the pharmaceutical industry have been more frequent in recent years, ranging from SAR studies to clinically relevant animal models of disease. A summary of the work published in this exciting new area is presented, outlining the broad applicability of this fundamental cellular mechanism across several disease indications. This area of research has matured to the level of advancing compounds into clinical trials: VX-74 (Pralnacasan) and VX-765 as anti-inflammatory agents, and IDN-6556, a pancaspase inhibitor as an anti-apoptotic agent.

Keywords: Caspase inhibitor, apoptosis, ICE, VX-740, VX-765, IDN-6556, a-Fas-induced liver model, Jurkat, peptidomimetics

« Previous

Rights & Permissions Print Export Cite as
© 2024 Bentham Science Publishers | Privacy Policy